Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

7(100.0%)

7Total

N/A(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04547257Not ApplicableActive Not Recruiting

Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19

Role: lead

NCT06637800Not ApplicableWithdrawn

Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)

Role: lead

NCT06655142Not ApplicableNot Yet Recruiting

OSCAR II STUDY - The ONCObind CTC Removal Study

Role: lead

NCT05011656Not ApplicableActive Not Recruiting

Blood Purification for the Treatment of Pathogen Associated Shock

Role: lead

NCT06481397Not ApplicableCompleted

OSCAR I STUDY - The ONCObind CTC Removal Study

Role: lead

NCT04413955Completed

Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA

Role: collaborator

NCT04260789Not ApplicableUnknown

Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection

Role: collaborator

NCT02914132Not ApplicableCompleted

Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis

Role: lead

All 8 trials loaded